SUPERNUS PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$20.76 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-09
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$20.76M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$13.64M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$10.35M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$1.32M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$35.96M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$39.29M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$2.66M.
- SUPERNUS PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$12.11M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|
| 2017-03-31 | -$20.76M 10-Q · filed 2017-05-09 | -$34.40M derived: sum of 2 quarters · filed 2017-05-09 | -$44.75M derived: sum of 3 quarters · filed 2017-05-09 | -$46.08M derived: sum of 4 quarters · filed 2017-05-09 | ||
| 2016-12-31 | -$13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$23.99M derived: sum of 2 quarters · filed 2017-03-16 | -$25.31M derived: sum of 3 quarters · filed 2017-03-16 | -$35.96M 10-K · filed 2017-03-16 | ||
| 2016-09-30 | -$10.35M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2017-01-20 | -$11.67M derived: sum of 2 quarters · filed 2017-01-23 | -$22.32M 10-Q · filed 2017-01-20 | -$35.19M derived: sum of 4 quarters · filed 2017-05-09 | ||
| 2016-06-30 | -$1.32M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2017-01-23 | -$11.97M 10-Q/A · filed 2017-01-23 | -$12.63M 10-Q · filed 2016-08-05 | -$24.84M derived: sum of 3 quarters · filed 2017-05-09 | -$33.60M derived: sum of 4 quarters · filed 2017-05-09 | |
| 2016-03-31 | -$10.65M 10-Q · filed 2017-05-09 | -$11.30M 10-Q · filed 2016-05-10 | -$23.52M derived: sum of 2 quarters · filed 2017-05-09 | -$32.28M derived: sum of 3 quarters · filed 2017-05-09 | -$38.82M derived: sum of 4 quarters · filed 2017-05-09 | |
| 2015-12-31 | -$12.87M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$21.63M derived: sum of 2 quarters · filed 2017-03-16 | -$28.17M derived: sum of 3 quarters · filed 2017-03-16 | -$39.29M 10-K · filed 2017-03-16 | ||
| 2015-09-30 | -$8.76M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2017-01-20 | -$15.30M derived: sum of 2 quarters · filed 2017-01-23 | -$26.42M 10-Q · filed 2017-01-20 | |||
| 2015-06-30 | -$6.54M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | -$17.66M 10-Q/A · filed 2017-01-23 | -$19.46M 10-Q · filed 2016-08-05 | |||
| 2015-03-31 | -$11.12M 10-Q/A · filed 2017-01-20 | -$11.15M 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | -$2.66M 10-K · filed 2017-03-16 | |||||
| 2013-12-31 | -$12.11M 10-K · filed 2014-03-21 | |||||
| 2012-12-31 | -$9.35M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$19.65M derived: sum of 2 quarters · filed 2014-03-21 | -$27.41M derived: sum of 3 quarters · filed 2014-03-21 | -$48.96M 10-K · filed 2014-03-21 | ||
| 2012-09-30 | -$10.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | -$18.06M derived: sum of 2 quarters · filed 2012-11-02 | -$39.61M 10-Q · filed 2012-11-02 | -$39.79M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2012-06-30 | -$7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$29.31M 10-Q · filed 2012-08-13 | -$29.49M derived: sum of 3 quarters · filed 2014-03-21 | -$19.14M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2012-03-31 | -$21.55M 10-Q · filed 2012-06-08 | -$21.73M derived: sum of 2 quarters · filed 2014-03-21 | -$11.39M derived: sum of 3 quarters · filed 2014-03-21 | -$7.56M derived: sum of 4 quarters · filed 2014-03-21 | ||
| 2011-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $10.17M derived: sum of 2 quarters · filed 2014-03-21 | $14.00M derived: sum of 3 quarters · filed 2014-03-21 | $8.29M 10-K · filed 2014-03-21 | ||
| 2011-09-30 | $10.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $14.17M derived: sum of 2 quarters · filed 2012-11-02 | $8.47M 10-Q · filed 2012-11-02 | |||
| 2011-06-30 | $3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$1.87M 10-Q · filed 2012-08-13 | ||||
| 2011-03-31 | -$5.70M 10-Q · filed 2012-06-08 | |||||
| 2010-12-31 | $25.82M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |